article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

But increased competition is on the horizon. Competition starts to heat up. In a case filed in California in 2021, Molina Healthcare claimed Jazz Pharmaceuticals engaged in a “comprehensive anticompetitive scheme to suppress generic competition for Xyrem,” abused the REMS program, and “engaged in sham patent litigation.”.

article thumbnail

470% price increases

World of DTC Marketing

net revenue for Imbruvica has increased from $492 million in 2014 to $4.3 billion in Imbruvica net revenue from Medicare Part D between 2014 and 2018. AbbVie has obtained or applied for over 250 patents on Humira to block competition from lower-priced biosimilars. AbbVie’s yearly U.S. billion in 2020. billion in 2020.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

UK authority asks for director ban for Alliance Pharma CEO

pharmaphorum

The UK Competition and Markets Authority (CMA) is seeking to disqualify Peter Butterfield, currently chief executive of Alliance Pharma, from serving as a company director. ” The action will only be heard if the Competition Appeal Tribunal (CAT) upholds the CMA’s findings against Alliance, it added. .”

Pharma 59
article thumbnail

Oncology biosimilar case studies: rituximab biosimilars

Pharmaceutical Technology

Rituxan received its first FDA approval in 1997 for the treatment of B-cell non-Hodgkin’s lymphoma (B-NHL) and reached peak global sales of $7.5bn in 2014. However, in the second year of biosimilar competition, Rituxan sales started to significantly erode. Rituxan’s success made it a prime target for biosimilar developers.

Sales 59
article thumbnail

Pharma says VPAS clawback jeopardises UK sector

pharmaphorum

” Since 2014, the repayment percentage detailed in the VPAS and predecessor the PPRS average at around 7%, before skyrocketing to 19% in 2022 ahead of a government agreed cap at 15%. Next year we must start again with a clean sheet of paper to agree on what an internationally competitive scheme looks like.”

Pharma 72
article thumbnail

New Web of Science Grants Index helps researchers develop more targeted grant proposals

Clarivate

Competition for funding is tough and researchers need help to make their grant applications stand out. While some funding programs have seen spending increase year over year, the competition remains tough: researchers often face just a 10 – 20% chance of winning a grant award. in 2022 was 20.7%.

article thumbnail

EU says Teva blocked generics to MS drug Copaxone

pharmaphorum

It was a $4 billion-a-year blockbuster at its peak in 2014, but shrank to around $1 billion last year and is predicted to make around $700 million this year. Our concern is that Teva may have misused the patent system to shield itself from competition.”